Mark Halvorson

Array ( [id] => 19170876 [patent_doc_number] => 20240156850 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING SOLID TUMORS [patent_app_type] => utility [patent_app_number] => 18/192226 [patent_app_country] => US [patent_app_date] => 2023-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13482 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18192226 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18581489 [patent_doc_number] => 20230263741 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-24 [patent_title] => Fusion Proteins Having a Toxin and Cancer Marker, Nanoparticles, and Uses Related Thereto [patent_app_type] => utility [patent_app_number] => 18/182682 [patent_app_country] => US [patent_app_date] => 2023-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13470 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18182682 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19004965 [patent_doc_number] => 20240069036 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-29 [patent_title] => METHOD FOR IDENTIFYING NEOANTIGENS ON CANCER CELLS BY USING XENOANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/181802 [patent_app_country] => US [patent_app_date] => 2023-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9112 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18181802 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20402277 [patent_doc_number] => 12492246 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-09 [patent_title] => Anti-FAM19A5 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 18/177334 [patent_app_country] => US [patent_app_date] => 2023-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 38 [patent_no_of_words] => 42156 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 166 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18177334 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19940295 [patent_doc_number] => 12312417 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-27 [patent_title] => Binding proteins 1 [patent_app_type] => utility [patent_app_number] => 18/164444 [patent_app_country] => US [patent_app_date] => 2023-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 17 [patent_no_of_words] => 21716 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18164444 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18710466 [patent_doc_number] => 20230333091 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-19 [patent_title] => NOVEL BLOOD CELL BIOMARKER FOR LATE ONSET ALZHEIMER'S DISEASE [patent_app_type] => utility [patent_app_number] => 18/161781 [patent_app_country] => US [patent_app_date] => 2023-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30662 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 130 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18161781 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18629533 [patent_doc_number] => 20230288415 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-14 [patent_title] => PREDICTION AND TREATMENT OF IMMUNOTHERAPEUTIC TOXICITY [patent_app_type] => utility [patent_app_number] => 18/062937 [patent_app_country] => US [patent_app_date] => 2022-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21766 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 141 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18062937 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18376032 [patent_doc_number] => 20230151114 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-18 [patent_title] => COMPOSITIONS AND METHODS OF TREATMENT OF SICKLE CELL ANEMIA AND BETA-THALASSEMIA [patent_app_type] => utility [patent_app_number] => 17/987058 [patent_app_country] => US [patent_app_date] => 2022-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4591 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17987058 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18467062 [patent_doc_number] => 20230201342 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-29 [patent_title] => USE OF LENVATINIB PLUS ANTI-PD-1 MONOCLONAL ANTIBODY IN PREPARATION OF ANTI-HEPATOMA DRUG [patent_app_type] => utility [patent_app_number] => 17/936398 [patent_app_country] => US [patent_app_date] => 2022-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2907 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17936398 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18166820 [patent_doc_number] => 20230033425 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-02 [patent_title] => HETERODIMERIC FC-FUSED PROTEINS [patent_app_type] => utility [patent_app_number] => 17/929282 [patent_app_country] => US [patent_app_date] => 2022-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57931 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17929282 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18451512 [patent_doc_number] => 20230192790 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => ANTI-TUMOUR RESPONSE TO MODIFIED SELF-EPITOPES [patent_app_type] => utility [patent_app_number] => 17/878533 [patent_app_country] => US [patent_app_date] => 2022-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25988 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17878533 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17960101 [patent_doc_number] => 20220340681 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-27 [patent_title] => DUAL ANTIGEN-INDUCED BIPARTITE FUNCTIONAL COMPLEMENTATION [patent_app_type] => utility [patent_app_number] => 17/842915 [patent_app_country] => US [patent_app_date] => 2022-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40036 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17842915 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17960312 [patent_doc_number] => 20220340892 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-27 [patent_title] => REDUCING BLOOD GLUCOSE, INSULIN RESISTANCE, OR HYPERLIPIDEMIA THROUGH RLIP76 PARTIAL DEPLETION [patent_app_type] => utility [patent_app_number] => 17/830027 [patent_app_country] => US [patent_app_date] => 2022-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12430 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17830027 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17867390 [patent_doc_number] => 20220290126 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => CANCER TREATMENT THROUGH RLIP76 PARTIAL DEPLETION [patent_app_type] => utility [patent_app_number] => 17/829768 [patent_app_country] => US [patent_app_date] => 2022-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12440 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17829768 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17928413 [patent_doc_number] => 20220323538 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-13 [patent_title] => METHODS FOR TREATING METASTATIC STAGE PROSTATE CANCER [patent_app_type] => utility [patent_app_number] => 17/829134 [patent_app_country] => US [patent_app_date] => 2022-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12951 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17829134 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18006322 [patent_doc_number] => 20220365088 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-17 [patent_title] => AUTOANTIBODY BIOMARKERS OF OVARIAN CANCER [patent_app_type] => utility [patent_app_number] => 17/826948 [patent_app_country] => US [patent_app_date] => 2022-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20385 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17826948 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18065550 [patent_doc_number] => 20220396637 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-15 [patent_title] => SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST INTRACELLULAR ANTIGENS [patent_app_type] => utility [patent_app_number] => 17/750341 [patent_app_country] => US [patent_app_date] => 2022-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36815 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17750341 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18296028 [patent_doc_number] => 20230105714 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-06 [patent_title] => ANTI-TIM-3 ANTIBODIES AND COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 17/741967 [patent_app_country] => US [patent_app_date] => 2022-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36481 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17741967 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17983856 [patent_doc_number] => 20220349892 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-03 [patent_title] => Use of TM9SF4 as a biomarker for tumor associated exosomes [patent_app_type] => utility [patent_app_number] => 17/737453 [patent_app_country] => US [patent_app_date] => 2022-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7808 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17737453 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17947096 [patent_doc_number] => 20220334115 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-20 [patent_title] => Screening and Assessment of Carcinomas [patent_app_type] => utility [patent_app_number] => 17/736535 [patent_app_country] => US [patent_app_date] => 2022-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20938 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17736535 [rel_patent_id] =>[rel_patent_doc_number] =>)